Important Safety Information Contact Us Prescribing Information

Patient Application Portal

Apply for patient assistance


  • Patients must be United States citizens or permanent residents, and must physically reside in the United States or its territories.
  • Proof of residency will not routinely be required but may be requested at any time through an audit (i.e, copy of valid driver’s license or recent utility bill).
  • Patients’ annual gross income must not exceed 250% of the Federal Poverty Level (FPL). Valid proof of income will be required.
  • Patients must be uninsured.
  • Patients must be under the care of a licensed prescriber with an established clinical practice located in the United States or its territories.
  • Patient diagnosis and dosing must be consistent with U.S. Food and Drug Administration regulations.
  • Patients will receive one (1) prescribed dose.
  • Patients receiving federally funded benefits will not be eligible to receive assistance under the Program. Such excluded patient benefits include, but may not be limited to: Medicare, Medicaid (including spend downs), Tricare, and VA benefits.

This program is subject to change or discontinuation by Kedrion Biopharma Inc. at any time, for any reason, and with or without prior notice. This portal is administered by Medmonk for the KEDRAB Patient Assistance Program.


KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.




Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB because KEDRAB may interfere with the anamnestic response to the rabies vaccine.


Hypersensitivity reactions, including anaphylaxis, may occur with KEDRAB. IgA deficient patients with antibodies against IgA are at greater risk. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions.


KEDRAB administration may interfere with the development of an immune response to live attenuated virus vaccines. If feasible, delay immunization with measles vaccine for 4 months, and other live attenuated virus vaccines for 3 months, after KEDRAB administration.


A transient rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results of serologic tests after KEDRAB administration.

Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs’ test).


Because KEDRAB is made from human plasma donors hyper-immunized with rabies vaccine, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma Inc. at 1-855-353-7466.


The most common adverse reactions in adult subjects treated with KEDRAB in clinical trials were injection site pain, headache, muscle pain, joint pain, dizziness, and fatigue.

In pediatric subjects treated with KEDRAB and a full course of rabies vaccine, the most common adverse reactions were injection site pain, headache, fever, pain in extremity, bruising (hematoma), fatigue, and vomiting.
Less common adverse reactions (≤5%) in pediatric patients were injection site redness (erythema), injection site swelling (edema), muscle pain, oral pain, and wound complication. Insomnia was reported as a less common adverse reaction (<5%) in pediatric patients occurring after 14 days of administration.


Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis and have a confirmed adequate rabies antibody titer should receive only a booster rabies vaccine (without KEDRAB) because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP).
KEDRAB can interfere with the immune response to the rabies vaccine. For this reason, do not exceed the recommended KEDRAB dose or give additional (repeat) doses of KEDRAB once rabies vaccination has been initiated.
KEDRAB can inactivate the rabies vaccine. For this reason, do not administer KEDRAB in the same syringe as the rabies vaccine or near the anatomical site of administration of the rabies vaccine.

Please see Full Prescribing Information for complete prescribing details.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-353-7466 or the FDA at 1-800-FDA-1088 or